The risk for urinary tract infections with sodium-glucose cotransporter 2 inhibitors: no longer a cause of concern?
Year: 2019
Type: editorial
Abstract: Sodium-glucose co-transporter-2 (SGLT2) inhibitors improve cardiovascular and renal outcomes in patients with type 2 diabetes, including those with diabetic kidney disease. However, the US Food and Drug Administration and European Medicines Agency warnings about potential adverse effects, such as urosepsis and pyelonephritis, based on post-marketing case reports, may deter physicians from prescribing these drugs. A recent evaluation of two large US-based databases of commercial claims failed to find evidence for an increased risk of urinary tract infection (UTI) or severe UTI in type 2 diabetes patients who were prescribed an SGLT2.
Source: Clinical Kidney Journal
DOI: 10.1093/ckj/sfz170
Authors: Pantelis A Sarafidis, Alberto Ortiz
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,335
Awards: Caracterización de nuevos factores nefroprotectores y aplicaciones terapéuticas, G1075404386, Nuevos abordajes para monitorizar y prevenir la necroinflamación en el daño renal agudo., Tratamiento personalizado de la Nefropatía por IgA, G1432989448, G1520406698, Reposicionamiento de nuevas formulaciones de 3,7-Dimethyl-1-(5-oxohexyl)-3,7-dihydro-1H-purine-2,6-diona para retrasar el envejecimiento por déficit de Klotho, G2170437373, G2312131674, G2605343809, G326643260, G3393410025, G3461049294, G4364775088, G5117888954, G6161449843, G6485122093, Multidimensional stratification for treatment of acute kidney injury, Nuevas aproximaciones terapéuticas para la protección tisular en la enfermedad renal, G999562601
OpenAlex ID: W2996314687